Taxotere Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Condition:   Hormone Receptor Positive HER-2 Negative Breast Cancer Interventions:   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Epirubicin;   Drug: Cyclophosphamide Sponsor:   Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 13, 2023 Category: Research Source Type: clinical trials

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Condition:   Hormone Receptor Positive HER-2 Negative Breast Cancer Interventions:   Drug: Docetaxel;   Drug: Carboplatin;   Drug: Epirubicin;   Drug: Cyclophosphamide Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 13, 2023 Category: Research Source Type: clinical trials